Panaphix (sodium metaarsenite) / Komipharm - LARVOL DELTA

Analgesic mechanism of Panaphix in spinal nerve-ligated rats: involvement of microglial inflammatory cytokines. (PubMed, Korean J Anesthesiol) - "PAX-1 demonstrated potent anti-allodynic and anti-inflammatory effects in an SNL-induced neuropathic pain model. These findings indicate that PAX-1 may exert analgesic effects primarily through modulation of IL-1β-mediated microglial activation, suggesting its therapeutic potential for neuropathic pain management."

Journal • Preclinical • Neuralgia • Oncology • Pain • IL1B • TNFA

Did Komipharm abort plan to develop Panaphix as Covid-19 drug? [Google translation] (Korea Biomedical Review) - "Komipharm International said it recently obtained the regulatory approval for a phase-2 clinical trial on Panaphix, an investigational drug, to treat glioblastoma (GBM)...The company had filed the Investigational New Drug (IND) application with the Ministry of Food and Drug Safety in September...The primary endpoint is progression-free survival."

IND • Non-US regulatory • Glioblastoma • Oncology